{"denoms":[{"counts":[{"groupId":"BG000","value":"529"},{"groupId":"BG001","value":"531"},{"groupId":"BG002","value":"1060"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 5 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 15 cycles. During the Q3W dosing period of pembrolizumab, participants received concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m\\^2 IV once per week (QW) for 5 or 6 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80 Gray Units (Gy) for volume-directed and 75 Gy for point-directed given with the total duration of radiation treatment not to exceed 50 days (with an extension to a maximum of 56 days for unforeseen delays).","id":"BG000","title":"Chemoradiotherapy + Pembrolizumab"},{"description":"Participants received placebo for pembrolizumab IV on Day 1 of each 3-week cycle (Q3W) for 5 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 15 cycles. During the Q3W dosing period of placebo, participants received concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m\\^2 IV once per week (QW) for 5 or 6 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80 Gray Units (Gy) for volume-directed and 75 Gy for point-directed given with the total duration of radiation treatment not to exceed 50 days (with an extension to a maximum of 56 days for unforeseen delays).","id":"BG001","title":"Chemoradiotherapy + Placebo for Pembrolizumab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.9","value":"49.4"},{"groupId":"BG001","spread":"12.3","value":"50.1"},{"groupId":"BG002","spread":"12.1","value":"49.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"529"},{"groupId":"BG001","value":"531"},{"groupId":"BG002","value":"1060"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"161"},{"groupId":"BG001","value":"173"},{"groupId":"BG002","value":"334"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"363"},{"groupId":"BG001","value":"356"},{"groupId":"BG002","value":"719"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"7"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"46"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"156"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"304"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"22"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"254"},{"groupId":"BG001","value":"264"},{"groupId":"BG002","value":"518"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"86"},{"groupId":"BG002","value":"164"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"50"}]}],"title":"CPS<1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"502"},{"groupId":"BG001","value":"498"},{"groupId":"BG002","value":"1000"}]}],"title":"CPS>=1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"10"}]}],"title":"Missing"}],"description":"Programmed cell death ligand 1 (PDL-1) status based on combined positive score (CPS) indicates tumor PD-L1 positivity using both tumor cells and inflammatory cells that are positive for PD-L1 by IHC. The number of participants with CPS\\<1 and CPS ≥1 at baseline is presented. Participants with CS \\<1 were classified as PD-L1 negative, and participants with CPS ≥1 were classified as PD-L1 positive.","paramType":"COUNT_OF_PARTICIPANTS","title":"PDL-1 Status","unitOfMeasure":"Participants"}]}